WO2021232067A8 - Stat3 inhibition for treatment and prevention of human coronavirus infection - Google Patents
Stat3 inhibition for treatment and prevention of human coronavirus infection Download PDFInfo
- Publication number
- WO2021232067A8 WO2021232067A8 PCT/US2021/070561 US2021070561W WO2021232067A8 WO 2021232067 A8 WO2021232067 A8 WO 2021232067A8 US 2021070561 W US2021070561 W US 2021070561W WO 2021232067 A8 WO2021232067 A8 WO 2021232067A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- prevention
- coronavirus infection
- treatment
- human coronavirus
- Prior art date
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 2
- 101150099493 STAT3 gene Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 241000007181 unidentified human coronavirus Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 244000309467 Human Coronavirus Species 0.000 abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 abstract 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 abstract 2
- 229940124790 IL-6 inhibitor Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The subject invention pertains to the use of STAT3 inhibitors for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering one or more STAT3 inhibitors, such as GLG-305 or GLG-805, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject and, optionally, one or more RNA kinase inhibitors, one or more IL-6 inhibitors and/or one or more Janus kinases (JAK) inhibitors. The subject invention further pertains to pharmaceutical compositions, packaged dosage formulations, and kits for treating or preventing human coronavirus infection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/998,862 US20230192786A1 (en) | 2020-05-15 | 2021-05-14 | Stat3 inhibition for treatment and prevention of human coronavirus infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063025719P | 2020-05-15 | 2020-05-15 | |
US63/025,719 | 2020-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021232067A1 WO2021232067A1 (en) | 2021-11-18 |
WO2021232067A8 true WO2021232067A8 (en) | 2022-09-15 |
Family
ID=78525147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/070561 WO2021232067A1 (en) | 2020-05-15 | 2021-05-14 | Stats3 inhibition for treatment and prevention of human coronavirus infection |
Country Status (2)
Country | Link |
---|---|
US (1) | US20230192786A1 (en) |
WO (1) | WO2021232067A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022076565A1 (en) * | 2020-10-07 | 2022-04-14 | Sorrento Therapeutics, Inc. | Salicylanilide analogs for use in the treatment of coronavirus |
CN114796177B (en) * | 2022-06-27 | 2022-09-30 | 广州国家实验室 | Anti-coronavirus medicine and application |
CN117599030A (en) * | 2023-12-08 | 2024-02-27 | 上海交通大学医学院 | Application of small molecule SC99 in preparation of anti-novel coronavirus drugs |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03010427A (en) * | 2001-05-17 | 2004-12-06 | Univ Utrecht | Corona-virus-like particles comprising functionally deleted genomes. |
WO2006002461A1 (en) * | 2004-07-05 | 2006-01-12 | Commonwealth Scientific And Industrial Research Organisation | Method and apparatus for operation of a cryogenic device in a gaseous environment |
US20060247318A1 (en) * | 2005-02-25 | 2006-11-02 | Hui Song | Small molecule inhibitors of STAT3 and the uses thereof |
WO2017181098A2 (en) * | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
WO2019018185A1 (en) * | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane derivatives for the treatment of filovirus infection |
-
2021
- 2021-05-14 WO PCT/US2021/070561 patent/WO2021232067A1/en active Application Filing
- 2021-05-14 US US17/998,862 patent/US20230192786A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021232067A1 (en) | 2021-11-18 |
US20230192786A1 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021232067A8 (en) | Stat3 inhibition for treatment and prevention of human coronavirus infection | |
MY196455A (en) | Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection | |
MX2023000798A (en) | Functionalized peptides as antiviral agents. | |
CR20230310A (en) | Prmt5 inhibitors | |
MX2023005984A (en) | Novel spiropyrrolidine derived antiviral agents. | |
WO2002066480A3 (en) | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders | |
MX2023005983A (en) | Novel spiropyrrolidine derived antiviral agents. | |
MX2023009222A (en) | Tricyclic-amido-bicyclic prmt5 inhibitors. | |
WO2021168483A3 (en) | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | |
MX2023001756A (en) | Functionalized peptides as antiviral agents. | |
WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
MX2022012056A (en) | Pyrrolopyrimidine amines as complement inhibitors. | |
MX2021014372A (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same. | |
MX2022006333A (en) | Tri-heterocyclic compound as jak inhibitor, and use thereof. | |
JOP20220075A1 (en) | Oral complement factor d inhibitors | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
MX2021009539A (en) | 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine. | |
WO2021016256A3 (en) | Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors | |
MX2023003576A (en) | Compound as akt kinase inhibitor. | |
MX2009007038A (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders. | |
MX2021013942A (en) | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor. | |
JOP20220076A1 (en) | Oral complement factor d inhibitors | |
MX2023013683A (en) | Fused isoxazolyl compounds as kat6a inhibitors. | |
MX2021003508A (en) | 5-azaindazole derivatives as adenosine receptor antagonists. | |
MX2021003901A (en) | 5-azaindazole derivatives as adenosine receptor antagonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21803872 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21803872 Country of ref document: EP Kind code of ref document: A1 |